Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Spatial transcriptomics identifies candidate stromal drivers of benign prostatic hyperplasia
Anna S. Pollack, Christian A. Kunder, Noah Brazer, Zhewei Shen, Sushama Varma, Robert B. West, Gerald R. Cunha, Laurence S. Baskin, James D. Brooks, Jonathan R. Pollack
Anna S. Pollack, Christian A. Kunder, Noah Brazer, Zhewei Shen, Sushama Varma, Robert B. West, Gerald R. Cunha, Laurence S. Baskin, James D. Brooks, Jonathan R. Pollack
View: Text | PDF
Research Article Cell biology Reproductive biology

Spatial transcriptomics identifies candidate stromal drivers of benign prostatic hyperplasia

  • Text
  • PDF
Abstract

Benign prostatic hyperplasia (BPH) is the nodular proliferation of the prostate transition zone in older men, leading to urinary storage and voiding problems that can be recalcitrant to therapy. Decades ago, John McNeal proposed that BPH originates with the “reawakening” of embryonic inductive activity by adult prostate stroma, which spurs new ductal proliferation and branching morphogenesis. Here, by laser microdissection and transcriptional profiling of the BPH stroma adjacent to hyperplastic branching ducts, we identified secreted factors likely mediating stromal induction of prostate glandular epithelium and coinciding processes. The top stromal factors were insulin-like growth factor 1 (IGF1) and CXC chemokine ligand 13 (CXCL13), which we verified by RNA in situ hybridization to be coexpressed in BPH fibroblasts, along with their cognate receptors (IGF1R and CXCR5) on adjacent epithelium. In contrast, IGF1 but not CXCL13 was expressed in human embryonic prostate stroma. Finally, we demonstrated that IGF1 is necessary for the generation of BPH-1 cell spheroids and patient-derived BPH cell organoids in 3D culture. Our findings partially support historic speculations on the etiology of BPH and provide what we believe to be new molecular targets for rational therapies directed against the underlying processes driving BPH.

Authors

Anna S. Pollack, Christian A. Kunder, Noah Brazer, Zhewei Shen, Sushama Varma, Robert B. West, Gerald R. Cunha, Laurence S. Baskin, James D. Brooks, Jonathan R. Pollack

×

Figure 6

IGF1 but not CXCL13 is expressed in stroma of human fetal prostates undergoing branching morphogenesis.

Options: View larger image (or click on image) Download as PowerPoint

IGF1 but not CXCL13 is expressed in stroma of human fetal prostates und...
Shown are cross sections of human fetal prostates at gestational ages (A–C) 12 weeks showing the urethra, (D–F) 14.6 weeks showing ductal budding from the urethra, and (G–I) 15 weeks showing ductal branching. (A, D, and G) H&E stains; scale bar is 500 μm. Note, the large black circle in G is a bubble under the coverslip. (B, E, and H) Two-color RNA in situ hybridization (RISH) of IGF1 (blue) and IGF1R (red). (C, F, and I) Two-color RISH of CXCL13 (blue) and CXCR5 (red). Arrows mark occasional epithelial cells with low-intensity CXCL13 and/or CXCR5 expression; scale bar is 500 µm, and all figure insets are an additional 3.2×–4.5× magnification.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts